Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers
Deborah F. Wilsker, Allison M. Barrett, Angie B. Dull, etc. Clin Cancer Res. 2019 May 15; 25(10): 3084–3095.
MDM2 and MDM4 are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors
Thomas P. Howard, Taylor E. Arnoff, Melinda R. Song, etc. Cancer Res. 2019 May 1; 79(9): 2404–2414.
Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models
Anna Capasso, Todd M. Pitts, Peter J. Klauck, etc. Anticancer Drugs. 2018 Oct; 29(9): 827–838.
Reactive astrocytic S1P3 signaling modulates the blood–tumor barrier in brain metastases
Brunilde Gril, Anurag N. Paranjape, Stephan Woditschka, etc. Nat Commun. 2018; 9: 2705.
Novel fluoroindenoisoquinoline non-camptothecin topoisomerase I inhibitors
Laetitia Marzi, Keli Agama, Junko Murai, etc. Mol Cancer Ther. 2018 Aug; 17(8): 1694–1704.
ALK inhibitor response in melanomas expressing EML4-ALK fusions and alternate ALK isoforms
Kasey L. Couts, Judson Bemis, Jacqueline A. Turner, etc. Mol Cancer Ther. 2018 Jan; 17(1): 222–231.
Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer
Matthew P. Goetz, Krishna R. Kalari, Vera J. Suman, etc. J Natl Cancer Inst. 2017 Jul; 109(7): djw306.
Analysis and Implementation of an Electronic Laboratory Notebook in a Biomedical Research Institute
Santiago Guerrero, Gwendal Dujardin, Alejandro Cabrera-Andrade, etc. PLoS One. 2016; 11(8): e0160428.